InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Bigham Michael, Chairman & CEO. Officer active across 2 companies, notably Adamas Pharmaceuticals Inc. In total, 14 filings have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €77k. History available since 2 June 2021. The latest transaction was disclosed on 2 February 2018 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Bigham Michael
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
23,255 shares@ US$4.3045.2% of flowCommon StockSEC:0000899243-23-019356:0
156,250 shares0Common StockSEC:0000904454-23-000476:0
45,000 shares0Common StockSEC:0000904454-22-000647:0
19,484 shares@ US$1.9820.7% of flowCommon StockSEC:0000904454-22-000621:0
6,000 shares@ US$3.4711.8% of flowCommon StockSEC:0000904454-22-000526:0
30,000 shares0Common StockSEC:0000904454-22-000504:0
143,182 shares0Common StockSEC:0000904454-22-000423:0
202,500 shares0Common StockSEC:0000904454-22-000262:0
5,059 shares@ US$4.4225.6% of flowCommon StockSEC:0000904454-21-000846:0
10,000 sharesCommon StockSEC:0001328143-21-000095:0
75,000 shares0Common StockSEC:0000904454-21-000626:0
85,909 shares0Common StockSEC:0000904454-21-000514:0
5,000 shares0Common StockSEC:0001328143-21-000054:0
30,000 sharesCommon StockSEC:0000904454-16-000934:0
14 of 14 declarations
About Bigham Michael
BIGHAM MICHAEL is Président-Directeur Général. He has 14 filings in total, and among the recent filings we track, they cover the period from 2016-02-08 to 2023-09-21. In this recent sample, sell amounts total 77319 EUR, buy amounts are 0 EUR, and the most frequent transaction nature is Attribution. His listed companies are Paratek Pharmaceuticals, Inc., where he is Exec. Chairman of the Board, and Adamas Pharmaceuticals Inc, where he is Director.
